Her2 Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Her2 Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 3

NCT06126640

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast C…

This study aims to Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants with Residual I…

China1,600 participantsStarted 2023-11-20

Treatment: SHR-A1811, Trastuzumab Emtansine

All recent trials (2 shown)

Active — Not RecruitingPhase 3

NCT04622319

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants W…

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease…

United States1,600 participantsStarted 2020-12-04

Treatment: DS-8201a, T-DM1